APRE supply chain intelligence for Aprea Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | at the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational dr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from APRE graph: at the product no longer meets the conditions for qualification or decide that the time period for FDA review or appr… |
| ORANY | ORANY | 72% | l disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from APRE graph: l disruption of our development programs, business operations, a breach of sensitive personal information or a loss … |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: Reciprocal relationship from APRE graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from APRE graph: Reciprocal relationship from SDGR g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ORANY | ORANY | 72% | l disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from APRE graph: l disruption of our development programs, business operations, a breach of sensitive personal information or a loss … |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success i… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: ates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We require that our CMO… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| APRE-DEBT-7805 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| APRE-DEBT-7804 | Warrants outstanding: 91 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| APRE-OWNER-MURCHINSON-LTD | Murchinson Ltd. | 95% | 13F/ownership overlay lists Murchinson Ltd.; shares held 340,139; ownership 2.97%; value $311,839; as of 2025-12-31. |
| APRE-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 40,950; ownership 0.36%; value $37,542; as of 2025-12-31. |
| APRE-OWNER-DRW-SECURITIES-LLC | DRW Securities, LLC | 95% | 13F/ownership overlay lists DRW Securities, LLC; shares held 120,651; ownership 1.05%; value $110,612; as of 2025-12-31. |
| APRE-OWNER-NANTAHALA-CAPITAL-MANAGEMENT-LLC | Nantahala Capital Management, LLC | 95% | 13F/ownership overlay lists Nantahala Capital Management, LLC; shares held 205,760; ownership 1.80%; value $188,640; as of 2025-12-31. |
| APRE-OWNER-AIGH-CAPITAL-MANAGEMENT-LLC | AIGH Capital Management LLC | 95% | 13F/ownership overlay lists AIGH Capital Management LLC; shares held 370,541; ownership 3.24%; value $339,711; as of 2025-12-31. |
| APRE-OWNER-SPHERA-FUNDS-MANAGEMENT-LTD | Sphera Funds Management Ltd. | 95% | 13F/ownership overlay lists Sphera Funds Management Ltd.; shares held 270,000; ownership 2.36%; value $247,536; as of 2025-12-31. |
| APRE-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 58,086; ownership 0.51%; value $53,253; as of 2025-12-31. |
| APRE-OWNER-CITADEL-ADVISORS-LLC | Citadel Advisors Llc | 95% | 13F/ownership overlay lists Citadel Advisors Llc; shares held 51,041; ownership 0.45%; value $46,794; as of 2025-12-31. |
| APRE-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 77,030; ownership 0.67%; value $70,621; as of 2025-12-31. |
| APRE-OWNER-JANE-STREET-GROUP-LLC | Jane Street Group, LLC | 95% | 13F/ownership overlay lists Jane Street Group, LLC; shares held 46,621; ownership 0.41%; value $42,742; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| IDYA | IDEAYA Biosciences, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| DRTS | Alpha Tau Medical Ltd. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 100.00 | 2 | |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 100.00 | 2 |